Geron Earnings Call Transcripts
Fiscal Year 2026
-
The meeting approved all board proposals, including director elections and incentive plan changes. Updates highlighted progress in clinical trials, organizational restructuring, and plans for ex-U.S. commercialization, with key trial results expected by 2028.
-
RYTELO's commercial rollout is accelerating, with updated NCCN guidelines supporting second-line use and strong uptake in community settings. Real-world and long-term data reinforce efficacy and safety, while financial guidance points to near-term profitability and strategic optionality.
-
RYTELO continues to gain traction in low-risk MDS, with strong Q1 revenue and expanding use in the second-line setting. Real-world evidence supports clinical trial results, and an interim readout for imetelstat in myelofibrosis is expected later this year.
-
Q1 2026 saw 31% year-over-year revenue growth and disciplined expense management, keeping the company on track for its 2026 guidance. U.S. RYTELO demand rose 6% sequentially, with commercial and medical strategies fueling further growth and European expansion plans underway.
-
Imetelstat, a first-in-class telomerase inhibitor, is driving growth in low-risk MDS with $184M revenue in 2025 and guidance of $220–$240M for 2026. Focus is on expanding second-line use, physician education, and advancing a pivotal myelofibrosis trial.
-
RYTELO achieved strong initial sales and is positioned for 20–30% growth in 2026, driven by second-line MDS market expansion and a focus on community adoption. The drug's unique mechanism and positive long-term data support confidence in further uptake, while a pivotal MF trial could unlock additional value.
-
RYTELO achieved $184 million in first-year sales, with 2025 guidance of $220–$240 million, driven by strategic focus on second-line MDS patients and refined commercial execution. EMA approval and ongoing ISTs support international expansion and broader clinical applications.
Fiscal Year 2025
-
RYTELO delivered $184M in 2025 net revenue, with strong Q4 growth and expanding prescriber base. 2026 guidance targets $220M-$240M revenue and reduced expenses, focusing on second-line, lower-risk MDS patients and continued commercial execution.
-
RYTELO's commercial uptake is improving as focus shifts to second-line MDS patients, supported by strong clinical data and updated guidelines. Physician engagement and targeted spending are driving growth, while the fully enrolled IMpactMF trial could expand the addressable market in coming years.
-
RYTELO's commercial growth has been slower than expected due to late-line use and limited US physician experience, but strategic initiatives are underway to shift adoption to earlier lines and expand market penetration. Updated guidelines and competitive dynamics are expected to support growth, with 2026 targeted as a pivotal year.
-
Q3 2025 saw $47M in revenue, 15% growth in prescribing accounts, and increased new patient starts in earlier lines, though overall demand was down 3% sequentially. Focus remains on driving Rytelo adoption, operational efficiency, and preparing for 2026 growth.
-
Q2 net revenue rose 24% sequentially to $49M, driven by new patient starts and expanded commercial execution. Commercial and medical teams grew by over 20%, and payer access improved to 90% of US covered lives. Cash reserves remain strong at $433M.
-
Q1 net revenue was $39.4M, down due to inventory drawdown, but demand and new site growth are positive. Commercial investments and expanded teams are expected to drive momentum, with early signs of increased uptake and favorable payer coverage.
-
Rytelo’s launch in 2024 saw strong initial uptake and nearly $77 million in revenue, with a focus on expanding community penetration and steady quarter-over-quarter growth. Strategic investments in sales, medical affairs, and a pivotal MF trial expected in late 2026 could double the drug’s opportunity.
Fiscal Year 2024
-
Rytelo's U.S. launch drove $76.5M in 2024 net product revenue, exceeding expectations, but revenue growth has flattened due to slower new patient starts, especially outside third-line use. Management expects to reach profitability in 2025 without additional financing, focusing on expanding adoption and operational execution.
-
Strong initial launch performance and robust financial strategy support confidence in reaching profitability without further equity raises. The product is gaining traction across key MDS patient segments, with EU launch preparations underway and myelofibrosis studies offering future growth potential.
-
Strong initial launch performance and financial position were highlighted, with broad market uptake and effective management of key patient segments. Strategic financing and plans for EU expansion were detailed, while guidance will follow after more quarters of data.
-
RYTELO's U.S. launch generated $28.2M in Q3 net revenue, exceeding expectations, with strong uptake across patient segments and robust payer coverage. New royalty and debt financings provide $250M in proceeds, supporting growth, EU launch prep, and a strong cash position.
-
RYTELO's U.S. launch saw strong early uptake, with 160 patients treated and broad account reach. Q2 revenue rose to $882,000, driven by initial sales, and the company maintains a solid cash position. Updated NCCN guidelines and regulatory exclusivity support long-term growth.
-
RYTELO, the first FDA-approved telomerase inhibitor for low- to intermediate-1-risk MDS with transfusion-dependent anemia, received broad approval with a manageable safety profile and no boxed warnings. Launch plans target rapid access, payer engagement, and inclusion in clinical guidelines.